Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Neocipran tablets are used to manage fibromyalgia. Neocipran is not approved for use in children.
Pharmacology
Milnacipran works as a potent inhibitor of neuronal norepinephrine and serotonin reuptake, acting on norepinephrine and serotonin in roughly a 1:3 ratio. Together these actions work synergistically to treat both depression and fibromyalgia, easing multiple fibromyalgia symptoms such as peripheral and central pain, low mood, and poor sleep and quality of life.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
The recommended dose of Milnacipran HCI for adults is 100 mg per day, taken as 50 mg twice daily. Depending on how well the medicine works and how well it is tolerated, the dose may be built up gradually according to the following schedule: on Day 1, 12.5 mg taken once; on Days 2 to 3, 25 mg per day, taken as 12.5 mg twice daily; on Days 4 to 7, 50 mg per day, taken as 25 mg twice daily; and after Day 7, 100 mg per day, taken as 50 mg twice daily. Based on how the individual patient responds, the dose may be increased to 200 mg per day, taken as 100 mg twice daily. Doses above 200 mg per day have not been studied.
Side Effects
The most commonly reported side effects are nausea, headache, constipation, dizziness, difficulty sleeping (insomnia), hot flushes, excessive sweating, vomiting, palpitations, a faster heart rate, dry mouth and raised blood pressure.
Cautions & Contraindications
Warnings & Precautions
Neocipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), similar to some medicines used to treat depression and other psychiatric disorders. Both adult and paediatric patients with depression or other psychiatric disorders may experience a worsening of their depression and/or the emergence of suicidal thoughts and behaviour (suicidality) or unusual changes in behaviour, whether or not they are taking these medicines, and this risk may persist until significant remission occurs. All patients being treated with medicines that inhibit the reuptake of norepinephrine and/or serotonin, for any indication, should be monitored appropriately and observed closely for clinical worsening, suicidality and unusual changes in behaviour, especially during the first few months of treatment or at times of dose changes, whether increases or decreases. A potentially life-threatening serotonin syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions have been reported with SNRIs and SNRIs alone, including Neocipran, but particularly when taken together with serotonergic drugs (including triptans), with drugs that impair the metabolism of serotonin (including MA01s), or with antipsychotics or other dopamine antagonists. Symptoms of serotonin syndrome may include changes in mental status (e.g. agitation, hallucinations, coma), autonomic instability (e.g. tachycardia, hyperthermia), neuromuscular abnormalities (e.g. hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g. nausea, vomiting, diarrhoea). Neocipran has been associated with reports of increased blood pressure.
Contraindications
Milnacipran must not be used in patients who are taking monoamine oxidase inhibitors (MA01s). Reports exist of serious, sometimes fatal, reactions in patients who received a serotonin reuptake inhibitor together with a monoamine oxidase inhibitor (MAGI). These reactions include hyperthermia, rigidity, myoclonus, and autonomic instability with possible rapid fluctuations of vital signs. There are also mental status changes, which range from extreme agitation to delirium and coma. In clinical trials, Milnacipran was linked to a higher risk of mydriasis. For this reason, Milnacipran should not be used in patients with uncontrolled narrow-angle glaucoma.
Pregnancy & Breastfeeding
Milnacipran has not been thoroughly studied in pregnant women, so its full risks during pregnancy remain unknown. In animal studies, rats given the drug during pregnancy showed an increased risk of fetal death. Milnacipran falls under pregnancy category C, meaning it may be prescribed to a pregnant woman if her physician determines that the potential benefits to her outweigh the possible risks to the unborn child.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Storage
Keep Milnacipran Hydrochloride in a cool, dry place. Protect it from light, and keep it where children can't reach it.
Common questions about Neocipran 50 mg
What is Neocipran 50 mg Tablet?
Neocipran 50 mg Tablet is a medicine that contains Milnacipran Hydrochloride. It is made by Ibn Sina Pharmaceutical Ind. Ltd. It belongs to the Serotonin-norepinephrine reuptake inhibitor (SNRI) group of medicines.
What is Neocipran used for?
Neocipran tablets are used to manage fibromyalgia. Neocipran is not approved for use in children.
What are the side effects of Neocipran?
The most commonly reported side effects are nausea, headache, constipation, dizziness, difficulty sleeping (insomnia), hot flushes, excessive sweating, vomiting, palpitations, a faster heart rate, dry mouth and raised blood pressure.
Can I take Neocipran during pregnancy or while breastfeeding?
Milnacipran has not been thoroughly studied in pregnant women, so its full risks during pregnancy remain unknown. In animal studies, rats given the drug during pregnancy showed an increased risk of fetal death. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
How should I store Neocipran?
Keep Milnacipran Hydrochloride in a cool, dry place. Protect it from light, and keep it where children can't reach it.
Is there a cheaper medicine with the same ingredient?
Neocipran is already among the lowest-priced brands of Milnacipran Hydrochloride at this strength.
Do I need a prescription for Neocipran?
Neocipran is a prescription (Rx) medicine. Take it as your doctor advises.